BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 32450869)

  • 1. Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies.
    Martinez FJ; Lipworth BJ; Rabe KF; Collier DJ; Ferguson GT; Sethi S; Feldman GJ; O'Brien G; Jenkins M; Reisner C
    Respir Res; 2020 May; 21(1):128. PubMed ID: 32450869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies.
    Martinez FJ; Rabe KF; Lipworth BJ; Arora S; Jenkins M; Martin UJ; Reisner C
    Int J Chron Obstruct Pulmon Dis; 2020; 15():99-106. PubMed ID: 32021148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD.
    Chen R; Zhong N; Wang HY; Zhao L; Mei X; Qin Z; Huang J; Assam PN; Maes A; Siddiqui S; Martin UJ; Reisner C
    Int J Chron Obstruct Pulmon Dis; 2020; 15():43-56. PubMed ID: 32021143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD.
    Maltais F; Ferguson GT; Feldman GJ; Deslee G; Bourdin A; Fjällbrant H; Siwek-Posłuszna A; Jenkins MA; Martin UJ
    Adv Ther; 2019 Sep; 36(9):2434-2449. PubMed ID: 31267366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD.
    Martinez FJ; Rabe KF; Ferguson GT; Fabbri LM; Rennard S; Feldman GJ; Sethi S; Spangenthal S; Gottschlich GM; Rodriguez-Roisin R; Arora S; Siler TM; Siddiqui S; Darken P; Fischer T; Maes A; Golden M; Orevillo C; Reisner C
    Chest; 2017 Feb; 151(2):340-357. PubMed ID: 27916620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA.
    Lipworth BJ; Collier DJ; Gon Y; Zhong N; Nishi K; Chen R; Arora S; Maes A; Siddiqui S; Reisner C; Martin UJ
    Int J Chron Obstruct Pulmon Dis; 2018; 13():2969-2984. PubMed ID: 30310273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler delivered using co-suspension delivery technology in Japanese patients with moderate-to-very severe chronic obstructive pulmonary disease.
    Gon Y; Nishi K; Sato K; Maes A; Siddiqui S; Hayashi N; Hirata H; Martin UJ; Reisner C
    Respir Investig; 2021 Jan; 59(1):135-144. PubMed ID: 32917556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD.
    Ferguson GT; Rodriguez-Roisin R; Reisner C; Maes A; Siddiqui S; Martin UJ
    Int J Chron Obstruct Pulmon Dis; 2018; 13():945-953. PubMed ID: 29606861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease.
    Hanania NA; Tashkin DP; Kerwin EM; Donohue JF; Denenberg M; O'Donnell DE; Quinn D; Siddiqui S; Orevillo C; Maes A; Reisner C
    Respir Med; 2017 May; 126():105-115. PubMed ID: 28427541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease.
    Reisner C; Fabbri LM; Kerwin EM; Fogarty C; Spangenthal S; Rabe KF; Ferguson GT; Martinez FJ; Donohue JF; Darken P; St Rose E; Orevillo C; Strom S; Fischer T; Golden M; Dwivedi S
    Respir Res; 2017 Jan; 18(1):8. PubMed ID: 28061907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial.
    Ferguson GT; Rabe KF; Martinez FJ; Fabbri LM; Wang C; Ichinose M; Bourne E; Ballal S; Darken P; DeAngelis K; Aurivillius M; Dorinsky P; Reisner C
    Lancet Respir Med; 2018 Oct; 6(10):747-758. PubMed ID: 30232048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts.
    Muro S; Sugiura H; Darken P; Dorinsky P
    Respir Res; 2021 Jun; 22(1):187. PubMed ID: 34182998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycopyrrolate/formoterol fumarate metered dose inhaler for maintenance-naïve patients with chronic obstructive pulmonary disease: a post-hoc analysis of the randomized PINNACLE trials.
    Zheng J; Xu JF; Jenkins M; Assam PN; Wang L; Lipworth BJ
    Respir Res; 2020 Mar; 21(1):69. PubMed ID: 32164675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD.
    Reisner C; Pearle J; Kerwin EM; Rose ES; Darken P
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1965-1977. PubMed ID: 29950826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study.
    Ichinose M; Fukushima Y; Inoue Y; Hataji O; Ferguson GT; Rabe KF; Hayashi N; Okada H; Takikawa M; Bourne E; Ballal S; DeAngelis K; Aurivillius M; Dorinsky P; Reisner C
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2979-2991. PubMed ID: 31920295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD.
    Martinez FJ; Fabbri LM; Ferguson GT; Orevillo C; Darken P; Martin UJ; Reisner C
    Chest; 2017 Dec; 152(6):1169-1178. PubMed ID: 28720336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS.
    Wang C; Yang T; Kang J; Chen R; Zhao L; He H; Assam PN; Su R; Bourne E; Ballal S; DeAngelis K; Dorinsky P
    Adv Ther; 2020 Apr; 37(4):1591-1607. PubMed ID: 32152869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD.
    Tashkin DP; Martinez FJ; Rodriguez-Roisin R; Fogarty C; Gotfried M; Denenberg M; Gottschlich G; Donohue JF; Orevillo C; Darken P; St Rose E; Strom S; Fischer T; Golden M; Reisner C
    Respir Med; 2016 Nov; 120():16-24. PubMed ID: 27817811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD.
    Kerwin EM; Spangenthal S; Kollar C; St Rose E; Reisner C
    Respir Res; 2018 Mar; 19(1):38. PubMed ID: 29506504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular safety profile of a fixed-dose combination of glycopyrrolate and formoterol fumarate delivered via metered dose inhaler using co-suspension delivery technology.
    Ferguson GT; Reisner C; Pearle J; DePetrillo P; Maes A; Martin UJ
    Pulm Pharmacol Ther; 2018 Apr; 49():67-74. PubMed ID: 29567116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.